1. Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.
- Author
-
Keck JW, Bulkow LR, Raczniak GA, Negus SE, Zanis CL, Bruce MG, Spradling PR, Teshale EH, and McMahon BJ
- Subjects
- Adolescent, Adult, Alaska, Child, Child, Preschool, Female, Hepatitis B immunology, Hepatitis B Vaccines administration & dosage, Humans, Infant, Infant, Newborn, Male, Population Groups, Time Factors, Hepatitis B prevention & control, Hepatitis B Antibodies blood, Hepatitis B Vaccines immunology, Hepatitis B virus immunology, Immunization, Secondary
- Abstract
Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF